Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Twelve-week, Efficacy and Safety Study Comparing Respimat ® Budesonide (100 and 200 mcg, 2 Puffs Bid) With Turbohaler ® Budesonide (200 mcg, 2 Puffs Bid) in Symptomatic Adult Moderate to Severe Asthmatic Requiring Inhaled Corticosteroids and Bronchodilator Therapy.

NCT02181335 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02181335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02181335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Twelve-week, Efficacy and Safety Study Comparing Respimat ® Budesonide (100 and 200 mcg, 2 Puffs Bid) With Turbohaler ® Budesonide (200 mcg, 2 Puffs Bid) in Symptomatic Adult Moderate to Severe Asthmatic Requiring Inhaled Corticosteroids and Bronchodilator Therapy.
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
October 31, 1998
Completion date
Not reported
Enrollment
684 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

asthma